SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.75
−0.14%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.41
- Revenue estimate
- $20.8M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.29
- EPS estimate
- -$0.43
- Revenue actual
- $26.7M
- Revenue estimate
- $19.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +17.8%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $52
- PT range
- $43 – $62
- Analysts
- 7
7 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026